Hazard ratios for overall survival and disease specific survival*
| Overall survival (n = 208) | Disease specific survival (n = 181) | |||
|---|---|---|---|---|
| HR (95% CI) | p Value | HR (95% CI) | p Value | |
| *Analyses were adjusted for sex, age, and American Joint Committee on Cancer (AJCC) stage. | ||||
| †Stage II and III cases only. | ||||
| HR (95% CI), Hazard ratio (95% confidence interval). | ||||
| Sex | ||||
| Males | 1 | 1 | ||
| Females | 0.93 (0.70–1.22) | 0.59 | 1.03 (0.76–1.38) | 0.86 |
| Age (per 10 y) | 1.03 (0.86–1.23) | 0.75 | 0.99 (0.82–1.20) | 0.91 |
| AJCC | ||||
| Stage I | 1 | 1 | ||
| Stage II | 2.7 (1.4–5.3) | 2.6 (1.0–6.5) | ||
| Stage III | 6.7 (3.5–12.8) | 11.1 (4.8–25.6) | ||
| Stage IV | 51.4 (26.8–98.5) | 83.7 (36.0–195) | ||
| Unknown | 15.0 (6.3–35.4) | <0.001 | 20.4 (7.1–59.2) | <0.001 |
| Degree of differentiation | ||||
| Well | 1 | 1 | ||
| Moderate | 0.87 (0.46–1.64) | 0.86 (0.43–1.73) | ||
| Poor | 1.38 (0.72–2.66) | 1.38 (0.67–2.82) | ||
| Unknown | 1.39 (0.68–2.83) | 0.02 | 1.41 (0.65–3.05) | 0.03 |
| Any adjuvant chemotherapy† | ||||
| No | 1 | 1 | ||
| Yes | 0.49 (0.30–0.78) | 0.003 | 0.42 (0.25–0.71) | 0.001 |
| Any adjuvant radiotherapy† | ||||
| No | 1 | 1 | ||
| Yes | 0.86 (0.50–1.48) | 0.58 | 0.95 (0.53–1.73) | 0.88 |